{
  "schema_version": "1.0",
  "type": "article",
  "title": "老花眼藥水 Ryzumvi 獲准，沒人搶著賣",
  "url": "https://drugnews.com.tw/articles/2026-10-22-ryzumvi-presbyopia-eye-drops-viatris-partner.html",
  "markdown_url": "https://drugnews.com.tw/articles/2026-10-22-ryzumvi-presbyopia-eye-drops-viatris-partner.md",
  "lang": "zh-Hant",
  "date": "2026-10-22",
  "publish_at": "2026-10-22T08:00:00+08:00",
  "updated_at": "2026-10-22",
  "category": "商業分析系列",
  "topic": "商業分析系列",
  "tags": [
    "老花眼藥水",
    "Ryzumvi",
    "老花眼",
    "Vizz",
    "Viatris"
  ],
  "summary": "40 歲後看手機要伸直手臂？美國剛核准第五款老花眼藥水 Ryzumvi，Viatris 卻在核准新聞稿裡說要找人代賣。賣得最好的 Vizz，一季也只有 170 萬美元。",
  "key_points": [
    "到 2027 年 6 月 30 日前，Viatris 的老花眼藥水 Ryzumvi 不會在美國正式上市治療老花；FDA 在 2026 年 10 月 16 日（美東時間）核准它的老花適應症，Viatris 同日表示正在評估找美國合作夥伴代賣。",
    "美國已有五款老花眼藥水（Vuity、Qlosi、Vizz、Yuvezzi、Ryzumvi），公開數字中最好的一季是 LENZ 的 Vizz：2026 年第二季產品淨營收 170 萬美元、約 2.7 萬盒，上市以來開過處方的醫師超過 1.3 萬人。",
    "Ryzumvi 三期 VEGA-3（545 人）在第 8 天點藥後 12 小時，27.2% 的人看近多讀 3 行以上，安慰劑組 11.5%；頭痛率 2.6%，但結膜充血達 21%。"
  ],
  "facts": [
    {
      "claim": "Ryzumvi 老花眼適應症 FDA 核准公告日（美東時間）",
      "value": "2026-10-16",
      "unit": "日期",
      "as_of": "2026-10-16",
      "source": "https://www.prnewswire.com/news-releases/viatris-receives-us-fda-approval-for-ryzumvi-for-the-treatment-of-presbyopia-302911593.html"
    },
    {
      "claim": "Ryzumvi 老花眼適應症仿單：結膜充血發生率",
      "value": 21,
      "unit": "%",
      "as_of": "2026-10-16",
      "source": "https://www.prnewswire.com/news-releases/viatris-receives-us-fda-approval-for-ryzumvi-for-the-treatment-of-presbyopia-302911593.html"
    },
    {
      "claim": "Ryzumvi 老花眼適應症仿單：點藥處刺激發生率",
      "value": 16,
      "unit": "%",
      "as_of": "2026-10-16",
      "source": "https://www.prnewswire.com/news-releases/viatris-receives-us-fda-approval-for-ryzumvi-for-the-treatment-of-presbyopia-302911593.html"
    },
    {
      "claim": "VEGA-3 三期試驗收案人數",
      "value": 545,
      "unit": "人",
      "as_of": "2025-06-26",
      "source": "https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia"
    },
    {
      "claim": "VEGA-3 第 8 天點藥後 12 小時看近多讀 3 行以上比例：phentolamine 組",
      "value": 27.2,
      "unit": "%",
      "as_of": "2025-06-26",
      "source": "https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia"
    },
    {
      "claim": "VEGA-3 第 8 天點藥後 12 小時看近多讀 3 行以上比例：安慰劑組",
      "value": 11.5,
      "unit": "%",
      "as_of": "2025-06-26",
      "source": "https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia"
    },
    {
      "claim": "VEGA-3 第 1 天點藥後 1 小時看近多讀 3 行以上比例：phentolamine 組對安慰劑組",
      "value": "20.6% 對 6.1%",
      "unit": "%",
      "as_of": "2025-06-26",
      "source": "https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia"
    },
    {
      "claim": "VEGA-3 頭痛發生率",
      "value": 2.6,
      "unit": "%",
      "as_of": "2025-06-26",
      "source": "https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia"
    },
    {
      "claim": "CLARITY 2：Vizz 點藥後 30 分鐘與 3 小時看近多 3 行比例",
      "value": 71,
      "unit": "%",
      "as_of": "2024-06-01",
      "source": "https://lenz-tx.com/?p=649"
    },
    {
      "claim": "CLARITY 2：Vizz 點藥後 10 小時看近多 3 行比例",
      "value": 40,
      "unit": "%",
      "as_of": "2024-06-01",
      "source": "https://lenz-tx.com/?p=649"
    },
    {
      "claim": "CLARITY 試驗 Vizz 扣除安慰劑的頭痛率",
      "value": 7.6,
      "unit": "%",
      "as_of": "2024-06-01",
      "source": "https://lenz-tx.com/?p=649"
    },
    {
      "claim": "Vizz FDA 核准日",
      "value": "2025-07-31",
      "unit": "日期",
      "as_of": "2025-07-31",
      "source": "https://www.hcplive.com/view/fda-approves-aceclidine-vizz-for-presbyopia-in-adults"
    },
    {
      "claim": "Vizz 2026 年第二季產品淨營收",
      "value": 1.7,
      "unit": "百萬美元",
      "as_of": "2026-06-30",
      "source": "https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"
    },
    {
      "claim": "Vizz 2026 年第二季賣出盒數",
      "value": 27000,
      "unit": "盒",
      "as_of": "2026-06-30",
      "source": "https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"
    },
    {
      "claim": "Vizz 上市至 2026 年第二季累計開過處方的醫師數",
      "value": "13,000+",
      "unit": "人",
      "as_of": "2026-06-30",
      "source": "https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"
    },
    {
      "claim": "LENZ Therapeutics 2026 年第二季淨損",
      "value": 31.9,
      "unit": "百萬美元",
      "as_of": "2026-06-30",
      "source": "https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"
    },
    {
      "claim": "LENZ Therapeutics 2026 年 6 月 30 日現金與有價證券",
      "value": 220,
      "unit": "百萬美元",
      "as_of": "2026-06-30",
      "source": "https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"
    },
    {
      "claim": "Tenpoint 為 Yuvezzi 上市募得的 B 輪與信用額度",
      "value": 235,
      "unit": "百萬美元",
      "as_of": "2026-01-29",
      "source": "https://pharmaphorum.com/news/tenpoint-eyes-presbyopia-drug-launch-after-fda-nod"
    },
    {
      "claim": "AbbVie 2022 年為 Vuity 認列的減損（pharmaphorum 報導）",
      "value": 770,
      "unit": "百萬美元",
      "as_of": "2026-01-29",
      "source": "https://pharmaphorum.com/news/tenpoint-eyes-presbyopia-drug-launch-after-fda-nod"
    },
    {
      "claim": "Vuity 核准時 AbbVie 估計的美國老花人口",
      "value": 128,
      "unit": "百萬人",
      "as_of": "2021-10-29",
      "source": "https://news.abbvie.com/2021-10-29-U-S-Food-and-Drug-Administration-Approves-VUITY-TM-pilocarpine-HCI-ophthalmic-solution-1-25-,-the-First-and-Only-Eye-Drop-to-Treat-Presbyopia-Age-Related-Blurry-Near-Vision"
    },
    {
      "claim": "Viatris 2022 年 11 月簽下 Nyxol（phentolamine）全球授權的簽約金",
      "value": 35,
      "unit": "百萬美元",
      "as_of": "2022-11-07",
      "source": "https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-22-040303/brhc10043812_ex99-1.htm"
    },
    {
      "claim": "Viatris 2023 年 1 月買下 Oyster Point 與 Famy 的總金額",
      "value": 750,
      "unit": "百萬美元",
      "as_of": "2023-01-05",
      "source": "https://www.dcatvci.org/top-industry-news/viatris-completes-750-m-acquisition-of-two-ophthalmology-companies/"
    },
    {
      "claim": "台灣做過雷射近視手術的人數（呂大文醫師說法）",
      "value": "100 萬+",
      "unit": "人",
      "as_of": "2026-02-07",
      "source": "https://health.ltn.com.tw/article/breakingnews/5335642"
    },
    {
      "claim": "Vizz 2025 年第四季營收（pharmaphorum 報導）",
      "value": 1.6,
      "unit": "百萬美元",
      "as_of": "2025-12-31",
      "source": "https://pharmaphorum.com/news/tenpoint-eyes-presbyopia-drug-launch-after-fda-nod"
    },
    {
      "claim": "Vizz 2026 年第一季產品淨營收（由上半年減第二季換算）",
      "value": 1.65,
      "unit": "百萬美元",
      "as_of": "2026-03-31",
      "source": "https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"
    }
  ],
  "sections": [
    "01｜老花為什麼點一滴眼藥水，就能看清楚一點？",
    "02｜睡前點一滴，隔天早上會差多少？",
    "03｜第一款就踩雷，第二代也賣不動",
    "04｜手上有眼科團隊的 Viatris，為什麼要找人賣？",
    "05｜台灣還買不到，誰最適合點？",
    "參考資料"
  ],
  "references": [
    {
      "title": "Viatris Receives U.S. FDA Approval for RYZUMVI for the Treatment of Presbyopia",
      "source": "Viatris（PR Newswire",
      "date": "2026-10-16",
      "url": "https://www.prnewswire.com/news-releases/viatris-receives-us-fda-approval-for-ryzumvi-for-the-treatment-of-presbyopia-302911593.html"
    },
    {
      "title": "Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia",
      "source": "Opus Genetics（Yahoo Finance",
      "date": "2026-10-16",
      "url": "https://finance.yahoo.com/healthcare/articles/opus-genetics-announces-fda-approval-160000544.html"
    },
    {
      "title": "FDA Approves RYZUMVI for Presbyopia; Viatris Seeks Commercial Partner",
      "source": "Clinical Trial Vanguard",
      "date": "2026-10-17",
      "url": "https://www.clinicaltrialvanguard.com/news/fda-approves-ryzumvi-for-presbyopia-viatris-seeks-commercial-partner/"
    },
    {
      "title": "Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint",
      "source": "Opus Genetics",
      "date": "2025-06-26",
      "url": "https://ir.opusgtx.com/press-releases/detail/490/opus-genetics-announces-vega-3-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-for-the-treatment-of-presbyopia"
    },
    {
      "title": "LENZ Therapeutics Reports Second Quarter 2026 Financial Results",
      "source": "LENZ Therapeutics（StockTitan",
      "date": "2026-08-11",
      "url": "https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html"
    },
    {
      "title": "FDA Approves Aceclidine (VIZZ) for Presbyopia in Adults",
      "source": "HCPLive",
      "date": "2025-07-31",
      "url": "https://www.hcplive.com/view/fda-approves-aceclidine-vizz-for-presbyopia-in-adults"
    },
    {
      "title": "LENZ Therapeutics announces results from Phase 3 CLARITY study",
      "source": "LENZ Therapeutics",
      "date": "2024-06-01",
      "url": "https://lenz-tx.com/?p=649"
    },
    {
      "title": "Tenpoint eyes presbyopia drug launch after FDA nod",
      "source": "pharmaphorum",
      "date": "2026-01-29",
      "url": "https://pharmaphorum.com/news/tenpoint-eyes-presbyopia-drug-launch-after-fda-nod"
    },
    {
      "title": "Tenpoint Therapeutics Announces FDA Approval of YUVEZZI",
      "source": "Tenpoint Therapeutics（Business Wire",
      "date": "2026-01-28",
      "url": "https://www.businesswire.com/news/home/20260128284402/en/Tenpoint-Therapeutics-Ltd.-Announces-FDA-Approval-of-YUVEZZI-the-First-and-Only-Combination-Eye-Drop-Approved-to-Treat-Presbyopia"
    },
    {
      "title": "U.S. FDA Approves VUITY, the First and Only Eye Drop to Treat Presbyopia",
      "source": "AbbVie",
      "date": "2021-10-29",
      "url": "https://news.abbvie.com/2021-10-29-U-S-Food-and-Drug-Administration-Approves-VUITY-TM-pilocarpine-HCI-ophthalmic-solution-1-25-,-the-First-and-Only-Eye-Drop-to-Treat-Presbyopia-Age-Related-Blurry-Near-Vision"
    },
    {
      "title": "AbbVie Form 10-Q for the quarter ended September 30, 2022",
      "source": "U.S. SEC",
      "date": "2022-09-30",
      "url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115222000045/abbv-20220930.htm"
    },
    {
      "title": "Ocuphire Pharma Enters Global License Agreement with Viatris for Nyxol",
      "source": "Ocuphire Pharma（SEC 8-K Exhibit 99.1",
      "date": "2022-11-07",
      "url": "https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-22-040303/brhc10043812_ex99-1.htm"
    },
    {
      "title": "Viatris Completes $750-M Acquisition of Two Ophthalmology Companies",
      "source": "DCAT Value Chain Insights",
      "date": "2023-01-05",
      "url": "https://www.dcatvci.org/top-industry-news/viatris-completes-750-m-acquisition-of-two-ophthalmology-companies/"
    },
    {
      "title": "「老花眼藥水」明年有望上市！醫曝6類人使用前要評估",
      "source": "東森新聞",
      "date": "2026-10-12",
      "url": "https://news.ebc.net.tw/news/health/575361"
    },
    {
      "title": "老花眼藥水新突破！FDA點頭放行 醫曝台灣為何買不到",
      "source": "自由健康網",
      "date": "2026-02-07",
      "url": "https://health.ltn.com.tw/article/breakingnews/5335642"
    }
  ],
  "images": [
    {
      "alt": "老花眼藥水的作用機制：多數藥拉緊瞳孔括約肌，Ryzumvi 放鬆擴大肌",
      "url": "https://drugnews.com.tw/assets/articles/ryzumvi-presbyopia-eye-drops-viatris-partner/figure-01.png"
    },
    {
      "alt": "Vizz 2026 年第二季：1.3 萬名醫師開過處方，當季產品淨營收 170 萬美元",
      "url": "https://drugnews.com.tw/assets/articles/ryzumvi-presbyopia-eye-drops-viatris-partner/figure-02.png"
    },
    {
      "alt": "美國五款老花眼藥水核准時間：Vuity、Qlosi、Vizz、Yuvezzi、Ryzumvi",
      "url": "https://drugnews.com.tw/assets/articles/ryzumvi-presbyopia-eye-drops-viatris-partner/figure-03.png"
    }
  ],
  "cover_image": "https://drugnews.com.tw/assets/articles/ryzumvi-presbyopia-eye-drops-viatris-partner/cover.png",
  "publisher": {
    "name": "Drugnews｜藥時事",
    "url": "https://drugnews.com.tw/",
    "profile": "https://drugnews.com.tw/brand-profile.json"
  },
  "citation": "Drugnews｜藥時事（2026-10-22）。老花眼藥水 Ryzumvi 獲准，沒人搶著賣。https://drugnews.com.tw/articles/2026-10-22-ryzumvi-presbyopia-eye-drops-viatris-partner.html",
  "disclaimer": "本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。",
  "translations": {}
}